J&J Recall Cuts Hospitalizations at Omicron – South African Study

CAPE TOWN – A booster dose of the single-dose COVID-19 vaccine from Johnson & Johnson Inc was 84% ​​effective in preventing hospitalization of South African healthcare workers who were infected during the spread of the variant Omicron, researchers said Thursday.

The real-world study, which was not peer reviewed, was based on a second dose of the J&J vaccine administered to 69,092 workers between November 15 and December 20.

A first cycle of inoculation has been shown to offer only considerably reduced protection against infection with Omicron, which is spreading rapidly in many countries after being first identified in late November in southern Africa and in Hong Kong.

However, several studies have suggested that a booster dose provides significant protection against serious illness caused by the variant.

The South African study showed that the effectiveness of the J&J vaccine in preventing hospitalization increased from 63% shortly after the booster was given to 84% 14 days later. Efficacy reached 85% one to two months after the booster.

“This reassures us that COVID-19 vaccines continue to be effective for the purpose for which they were designed, which is to protect people from serious illness and death,” said Linda-Gail Bekker, co-investigator principal of the study.

“This is yet another piece of evidence that we haven’t lost that impact even in the face of a heavily mutated variant.”

Bekker said the jury was “still out” on the question of other J&J shooting boosters.

“What we’re showing is that two doses really restore full protection, and I don’t think we can extrapolate from that that we’re going to need a third or fourth boost.”

The researchers said their analysis had several limitations, including short follow-up times, which averaged eight days for healthcare workers who had received their booster in the previous 13 days, or 32 days for those who had. received a booster 1 to 2 months earlier, which could affect the overall effectiveness of the vaccine.

Another South Africa-based study this month showed that an initial round of inoculation with two doses of Pfizer-BioNTech’s COVID-19 vaccine was less effective in South Africa in keeping people infected with the virus. out of hospital since the emergence of the Omicron variant.

Reviewer overview

J&J Recall Cuts Hospitalizations at Omicron - South African Study - /10

Summary

CAPE TOWN - A booster dose of the single-dose COVID-19 vaccine from Johnson & Johnson Inc was 84% ​​effective in preventing hospitalization of South African healthcare workers who were infected during the spread of the variant Omicron, researchers said Thursday.

0 Bad!